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CLINICAL AND LABORATORY TOLERANCE STUDIES IN VOLUNTEERS
GIVEN ORAL METHOXSALEN
HAROLD A. TUCKER, M.D.'
With the introduction of new or "improved'
dosage forms of accepted drugs, it is desirable to
study them carefully from the standpoint of
"patient acceptance", as well as for evidence of
objective untoward effects. It is the purpose of
this report to summarize such an evaluation of
protection coated compressed tablets, each con-
taining 10 mg. of methoxsalen*. Further, an
attempt will be made to examine and evaluate
the available evidence relating to purported
hepatic intolerance of this chemical in man.
MATERIAL AND METHODS
Two protection-coated 10 mg. tablets of meth-
oxsalen were administered daily for 21 days to
each of 100 healthy adult male volunteers. Twenty
similar subjects were given two gelatin capsules
each containing 10 mg. of the drug each morning.
All men were checked daily for subjective com-
plaints and observed for such objective develop-
ments as vomiting, cramping or diarrhea. During
the trial period there was little or no exposure to
sunlight.
In all subjects the following laboratory tests
were done at 0, 10 and 21 days: total serum bili-
rubin, thymol turbidity (0.5 and 18 hour), zinc
turbidity and cephalin-cholesterol flocculation
(24 and 48 hour). In addition, 50 men receiving
the tablets had hemograms, urinalyses and brom-
sulfalein retention studies at those times.
Using the method of Malloy and Evelyn (1),
the range of normal for total serum bilirubin was
up to 1.0 mg. per cent, with a transition zone up
to 1.5 mg. per cent (2). Zinc turbidity was carried
out according to Kunkel et at. (3); normal range
was two to ten units. Thymol turbidity, using the
method of Maclagan, as modified by Ducci (4),
ranged normally up to four units. The cephalin-
cholesterol flocculation tests were done according
to Hanger (5) and 0 to 1+ in 48 hours was con-
sidered normal. Finally, five mg/kg of body weight
of bromsulfalein was injected intravenously.
Retention greater than five per cent 45 minutes
later was considered abnormal (6). The correc-
tions for body weight advised by Zieve and Hill
were applied (2).
'Department of Clinical Investigation, The
Upjohn Company, Kalamazoo, Michigan.
* The trade name for methoxsalen, Upjohn, is
Meloxine®.
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Hemogram and urinalysis technics were stand-
ard ones.
REsULTs
Only three of the 100 subjects given coated
tablets of methoxsalen (Nos. 6, 28, 33) com-
plained of symptoms which might properly be
ascribed to the drug. These included mild gastro-
intestinal distress which was evident only during
the first five to ten days of the study. Discomfort
developed in these within about half an hour
following ingestion of the tablets and was usually
described as indigestion. There was no nausea,
vomiting, cramping or diarrhea. The other 97,
as well as the 20 subjects given 10 mg. capsules,
all stated they were totally unaware of any drug
effect. Cursory physical examinations of all
volunteers revealed no drug-associated changes.
It was concluded that on this dosage regimen
methoxsalen was exceedingly well tolerated in
both dosage forms.
All blood, urine and hepatic function tests at
0, 10 and 21 days were within normal limits. No
cephalin-cholesterol flocculation result exceeded
1 + at either 24 or 48 hours. The remainder of the
results of the liver function profiles have been
summarized in Table 1. It was concluded that on
this dosage regimen, involving a total of 2,520
patient-days' exposure to risk, methoxsalen had
no demonstrable untoward effects.
DIscussIoN
In planning a study such as this one a certain
arbitrariness must be applied. Dosage ordinarily
used may be that recommended for actual clin-
ical use (as was done in this case), or may be
severalfold greater.
The duration of the experiment, which could
be indefinite, was here set at 21 days for three
reasons. First, this time exceeds by half again
the 14-day course of methoxsalen recommended
for increasing skin tolerance to solar exposure,
thus giving a reasonable margin of safety. Sec-
ondly, on the basis of prior experience with agents
which did induce untoward effects, it was felt
real toxicity would probably become apparent
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TABLE 1
Average Responses, Standard Deviations and
Ranges of Liver Function Tests on 120 Subjects
Who Received 20 Mg. Methoxsalen Daily for
Three Weeks
Test and Time Average
Stan-
atinn
Range
BSP5:
Pre-treatment
lodays
2ldays
2.49
2.39
2.25
0.84
0.89
0.81
1.0 —4.5
1.0—5.0
1.0—4.5
Bilirubin
Pre-treatment
10 days
21 days
0.614
0.597
0.569
0.19
0.19
0.18
0.30—1.35
0.30—1.00
0.25—1.00
Zinc turbidity:
Pre-treatment
10 days
21 days
2.81
2.73
2.74
0.88
0.84
0.85
0.65—4.5
1.0—4.5
1.5 —4.5
Thymol turbidity
(30 mm.):
Pre-treatment
10 days
21 days
(18 hr.):
Pre-treatment
10 days
21 days
1.17
1.18
1.22
1.30
1.32
1.35
0.48
0.45
0.45
0.51
0.49
0.52
0.5 —3.5
0.5—3.0
0.5—3.0
0.5 —3.5
0.5—3.5
0.5 —3.0
* BSP on 50 subjects only.
during this period of time. Finally, an experiment
designed without matching placebo controls
is at the mercy of chance; a spate of hepati-
tis in this population would have given alto-
gether different results. Even illnesses unrelated
specifically to the liver might well have caused
abnormal cephalin-cholesterol flocculation or
sine and thymol turbidity reactions, because
they are nonspecific tests. To do such an experi-
ment, one must be sincerely convinced there is
no real inherent toxicity in the drug to be studied,
under the given test conditions, and be willing to
accept the risk of fortuitous events. Because of
these uncontrolled features, however, such studies
should not be unduly prolonged.
Another arbitrary decision involved the labora-
tory tests to be employed. The excellent model of
Fitzpatrick, imbrie, and Labby (7) was followed
except that serum bilirubin tests were added.
Sensitive qualitative, "screening" procedures
were accompanied by tests designed to indicate
the degree or extent of damage, should such be
encountered. The bromsulfalein-retention test is
the most reliable one available for approximating
total hepatic function in non-jaundiced subjects;
it provides one of the most sensitive screening
tests of the excretory function. In the abnormal
range, the serum bilirubin test is also a reliable
index of this liver function (8). Of the tests de-
pendent on alterations in serum proteins,
eephalin-eholesterol flocculation is a sensitive
screen for early or subclinical damage involving
hepatie cell injury or autolysis. The zinc and
thymol turbidity procedures, reflecting as they
do increased or abnormal serum globulins, to-
gether or separately give a reliable indication of
the extent or degree of hepatocellular disease.
Altogether, it is unlikely that significant hepatic
damage, drug-induced or otherwise, would have
gone unnoted.
Furocoumarins have been widely used for
centuries in the Middle and Far East for the
treatment of vitiligo; the one best known in the
United States is methoxsalen (8-methoxypsora-
len). Clinicians in foreign areas do not seem to be
impressed with risks associated with systemic
psoralea administration. In this country, how-
ever, these have perhaps been given emphasis
out of proportion to the evidence which is,
briefly, as follows:
A 1953 publication (9) pointed attention to
results of eephalin-eholesterol flocculation tests
which were in fact within normal limits for the
method used (7). Further, as its originator has
pointed out, this procedure is not necessarily an
adequate test of hepatie function (10). It is of
optimal significance when used as a part of a
battery or "profile" of tests.
A 1956 report of abnormal bromsulfalcin reten-
tion in two of 22 subjects receiving methoxsalen
(11) loses significance because pretreatment
baseline values were not established. More re-
cently further studies on this test in 27 subjects
given 20 mg. of methoxsalen daily for varying
periods were reported (12). One patient had 5
per cent retention at one month, 10 per cent at
two months and 20 per cent at the end of the
third month, so the drug was discontinued;
there was no clinical jaundice. Eleven months
later the test showed 14 per cent retention.
Another patient had "less than eight per cent
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retention" at one month, six per cent at two
months and ten per cent at the end of the third
month; treatment was stopped. A third patient
had a serum bromsulfalcin retention of eight
per cent before methoxsalen was given. There
was no change in four subsequent tests over a
period of nine months during which the patient
received 20 mg. of drug daily. One hundred and
sixty-six serum bromsulfalcin tests on the re-
maining 24 patients were within normal limits
(less than five per cent retention). One wonders,
of course, what a similar number of tests in 27
"normal controls" would have shown, and
whether the subjects with elevated retention
differed in other respects from those who had
normnl tests.
In addition, there have been sporadic, un-
published reports of abnormal liver function
tests in patients receiving 8-methoxypsoralen for
the treatment of vitiligo (7).
Balanced against these data, which might sug-
gest that methoxsalcn may play the unsavory
role of an hepatotoxin, arc three bodies of evi-
dence. First, clinical efforts to induce these pur-
ported changes have not succeeded. Fitzpatrick
et at. (7) have described a placebo-controlled
approach in 24 adult males. Twelve took 30 mg.
of mcthoxsalcn daily for three months, the others
took placebos. Batteries of liver function tests
were done at 0, 1, 2, and 3 months. Using brom-
sulfalcin retention, ccphalin-cholcstcrol floccula-
tion, zinc and thymol turbidity tests, no subject
had a change in liver function tests that would
indicate liver damage. The second completely
negative study, here described, involved 120 test
subjects. Prolonged administration has also been
tried; two patients, for example, have taken 70
mg. of methoxsalcn daily for over one year with-
out laboratory or clinical evidence of untoward
effects (13). Goldman has observed three patients
who have ingested 20 mg. daily for over two
years without demonstrable ill effects on "liver
profile or otherwise" (14). The statistical limita-
tions of these data are recognized, but it is fair
to point out, as Labby has done (15), that "con-
siderable practical experience in the interpreta-
tion of liver tests in the field of hcpatic injury
carries with it a more favorable confidence factor
[than analysis of these comparatively small
series might suggest]—one that probably does
not lend itself easily to statistical expression."
Secondly, jaundice has never been rcportcd in
subjects receiving 8-methoxypsoralcn where other
etiologies have been satisfactorily eliminated (7).
And finally, it is now known that furocou-
marins arc present in a wide variety of plants,
many with edible parts (e.g., members of lime,
fig, parsley, parsnip, carrot families, etc.). It
has been estimated (16) that an average stalk of
celery may contain one mg. or more of psoralcns.
Instead of being concerned further about
purported toxicity, perhaps future research
effort should be focused on finding out whether
the naturally occurring furocoumarins, including
methoxsalen, participate in the physiology and
biochemistry of normal human skin.
SUMMARY
A battery of liver function tests was carried
out on 120 adult male volunteers before treat-
ment and on the tenth and twenty-first days of
daily ingestion of 20 mg. of mcthoxsalen. All
results were within normal limits. Minor subjec-
tive side effects were reported by three subjects.
It was concluded that under the conditions of
the study, patient acceptance was excellent and
mcthoxsalen was nontoxic.
It was pointed out that there has been reported
no unequivocal evidence that 8-methoxypsoralcn
has an adverse effect on liver function. On the
contrary, studies designed to show liver damage
were entirely negative, in keeping with the fact
that jaundice has never been reported in subjects
receiving methoxsalcn where other etiologies
have been satisfactorily ruled out. Further, the
widespread natural occurrence of furocoumarins
in plants with edible parts, many in general usc,
suggests that the psoralcns may be a component
of normal diet and even play a role in the phys-
iology and biochemistry of normal human skin.
Dr. 0. S. Carpenter kindly carried out the sta-
tistical procedures cited in Table 1.
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